Research progress in anaplastic lymphoma kinase inhibitors
The anaplastic lymphoma kinase(ALK)gene is fused with the echinoderm microtubule-associated protein like 4(EML4)gene due to a chromosomal translocation,resulting in the formation of the potent oncogenic EML4-ALK fusion gene.The EML4-ALK fusion gene is a potent oncogenic gene that contributes to cellular carcinogenesis,which accounts for 3％～7％of non-small cell lung cancer(NSCLC).With the progress in tumor molecular targeted therapy,many ALK tyrosine kinase inhibitors(ALK-TKI)have been gradually used for EML4-ALK-positive NSCLC patients,showing better efficacy than that of traditional chemotherapy.Therefore,the development of ALK small molecule inhibitors has become a research hotspot.This paper reviewed some literatures on small molecule ALK inhibitors and their anticancer application in recent years.
mesenchymal lymphoma kinasesmall molecule inhibitortumornon-small cell lung cancer
万方数据
维普
